Loading…
Loading…
DVA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DVA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DVA and 80,000+ other tickers.
See exactly how DVA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DVA and 80,000+ other tickers.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The…
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
In fact, it's a healthcare company. It is a strong player in its chosen niche.
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.